These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1322029)

  • 1. Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis.
    Nicolini FA; Nichols WW; Saldeen TG; Khan S; Mehta JL
    Am Heart J; 1992 Aug; 124(2):280-8. PubMed ID: 1322029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA; Lee P; Rios G; Kottke-Marchant K; Topol EJ
    Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
    Nichols WW; Nicolini FA; Khan S; Saldeen TG; Mehta JL
    Am Heart J; 1993 Aug; 126(2):285-92. PubMed ID: 7687816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K; Kloner RA
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
    Martin U; Fischer S; Sponer G
    J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T; Gold HK; Leinbach RC; Yaoita H; Fallon JT; Guerrero L; Napier MA; Bunting S; Collen D
    Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
    Biemond BJ; Levi M; Coronel R; Janse MJ; ten Cate JW; Pannekoek H
    Circulation; 1995 Feb; 91(4):1175-81. PubMed ID: 7850956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis.
    Sakamoto T; Ogawa H; Yasue H; Oda Y; Kitajima S; Tsumoto K; Mizokami H
    Circulation; 1994 Jul; 90(1):427-32. PubMed ID: 8026029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
    Mickelson JK; Simpson PJ; Cronin M; Homeister JW; Laywell E; Kitzen J; Lucchesi BR
    Circulation; 1990 Feb; 81(2):617-27. PubMed ID: 2105175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
    Shebuski RJ; Stabilito IJ; Sitko GR; Polokoff MH
    Circulation; 1990 Jul; 82(1):169-77. PubMed ID: 2114233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Komjathy SF; Poulton J; Stafford JL; Godard J
    Circulation; 1994 Jan; 89(1):361-5. PubMed ID: 8281671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA; Mellott MJ; Garsky VM; Shebuski RJ
    Pharmacology; 1991; 42(6):340-8. PubMed ID: 1946598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
    Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
    Yasuda T; Gold HK; Fallon JT; Leinbach RC; Garabedian HD; Guerrero JL; Collen D
    J Am Coll Cardiol; 1989 May; 13(6):1409-14. PubMed ID: 2495318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
    Mehta JL; Chen L; Nichols WW; Johannesen M; Bregengård C; Hedner U; Saldeen TG
    J Am Coll Cardiol; 1995 Mar; 25(3):753-60. PubMed ID: 7860925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator.
    Shebuski RJ; Sitko GR; Claremon DA; Baldwin JJ; Remy DC; Stern AM
    Blood; 1990 Apr; 75(7):1455-9. PubMed ID: 1969293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
    Nicolini FA; Mehta JL; Nichols WW; Saldeen TG; Grant M
    Circulation; 1990 Mar; 81(3):1115-22. PubMed ID: 1689620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.